Financhill
Back

Denali Therapeutics Quote, Financials, Valuation and Earnings

U.S. Government Report Alert Tuesday

Discover the Secret Loophole
Buy
68

DNLI
Denali Therapeutics

Last Price:
29.91
Seasonality Move:
6.34%

7 Day Trial

ALL ACCESS PASS

$ 7

The Mysterious VC Firm Behind Nvidia's Secret Weapon

Details Here!

Denali Therapeutics Price Quote

$29.91
-1.67 (-5.29%)
(Updated: November 12, 2024 at 5:40 PM ET)

Denali Therapeutics Key Stats

Buy
68
Denali Therapeutics (DNLI) is a Buy

Day range:
$31.56 - $33.33
52-week range:
$14.56 - $33.33
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
14.50
P/B ratio:
3.45%

Volume:
795K
Avg. volume:
682.7K
1-year change:
94.7%
Market cap:
$4.5B
Revenue:
$330.5M
EPS:
$-2.76

How Much Does Denali Therapeutics Make?

Data Unavailable

Is Denali Therapeutics Growing As A Company?

Data Unavailable

Denali Therapeutics Stock Price Performance

What Is Denali Therapeutics 52-Week High & Low?

Denali Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Denali Therapeutics?

Is Denali Therapeutics Cash Flow Positive?

  • What Is DNLI Cash Flow From Operations?
    Cash flow from operations (TTM) is -$362.6M
  • What Is Denali Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $493.2M
  • What Is Denali Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$187.9M

Denali Therapeutics Return On Invested Capital

Data Unavailable

Denali Therapeutics Earnings Date & Stock Price

Denali Therapeutics Competitors

  • Who Are Denali Therapeutics's Competitors?
    Below is a list of companies who compete with Denali Therapeutics or are related in some way:
    • AIM ImmunoTech Inc (AIM)
    • Armata Pharmaceuticals Inc (ARMP)
    • Perspective Therapeutics Inc (CATX)
    • Electromed Inc (ELMD)
    • Protalix BioTherapeutics Inc (PLX)

Denali Therapeutics Dividend Yield

Denali Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0.3%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 10
Hold Recommendations: 3
Sell Recommendations: 0
Price Target: 41.31
Upside from Last Price: 30.8%

Major Shareholders

  • How many DNLI shares are owned by institutional investors?
    243.1M DNLI shares are owned by institutional investors
  • How many DNLI shares are owned by insiders?
    2.7M DNLI shares are owned by insiders